AI assistant
Inmune Bio, Inc. — Director's Dealing 2019
May 21, 2019
34518_dirs_2019-05-20_edbbfe0d-d656-4bcd-a3ad-241f397cce92.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: Inmune Bio, Inc. (INMB)
CIK: 0001711754
Period of Report: 2019-05-06-06:00
Reporting Person: Moss David J (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-05-06-06:00 | Common Stock | P | 5000 | $10.71 | Acquired | 1210417 | Direct |
Footnotes
F1: Includes 5,000 shares of the Issuer's common stock acquired by the Reporting Person in connection with a private placement consummated as of May 6, 2019.
F2: On May 16, 2019, the Issuer and Mr. Moss entered into an Amendment to the Securities Purchase Agreement, pursuant to which the definition of "purchase price" in the Securities Purchase Agreement, dated May 6, 2019, entered into by and between the Issuer and Mr. Moss was amended to be $10.71 per share (from $9.00). On May 16, 2019, Mr. Moss paid the Issuer $8,550, representing the additional amount of the purchase price.